Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Privately-held Switzerland-headquartered Ferring Pharmaceuticals and Merck & Co, through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Hemorrhage Prevention). 22 February 2018
The chronic obstructive pulmonary disorder (COPD) space is shaping up to become one of pharma’s biggest battle grounds in the next few years as some of the industry’s biggest players compete for dominance. 22 February 2018
The Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the use FluMist Quadrivalent (influenza vaccine live, intranasal) in the US for the 2018-2019 season. 22 February 2018
A new real-world analysis published today in the Journal of Clinical Psychiatry illuminates the significant economic burden of treatment-resistant depression (TRD) on healthcare costs, resource utilization, work productivity and employment, underscoring the critical need to treat the illness with a greater urgency. 21 February 2018
With 2017 sales growth at 21.5% and shares in the company up 96% since the beginning of last year, everything is going right for Ipsen at the moment. 21 February 2018
French drugmaker Ipsen has entered into a strategic agreement to develop and commercialize innovative therapies with UK-based life sciences firm Arix Bioscience. 21 February 2018
California, USA-based Ionis Pharmaceuticals has expanded its collaboration with Anglo-Swedish pharma major AstraZeneca in a deal that could see it earn as much as $330 million including success-based milestones. 20 February 2018
PDL BioPharma today officially announced it will no longer pursue its proposed acquisition of US modified-release drug delivery specialist Neos Therapeutics. 20 February 2018
Over half a billion pounds’ ($700 million) worth of healthcare agreements were signed between UK and Chinese groups in the course of the Prime Minister’s recent visit to China, it has been revealed. 20 February 2018
Merck KGaA today announced the creation of ExploreBio, a pre-seed-investment vehicle by four investment funds targeted at early-stage companies in the biotechnology landscape in Israel. 20 February 2018
A new firm dubbed Gain Therapeutics has been spun out of Barcelona’s Minoryx Therapeutics, centered around the SEE-Tx platform to develop treatments for rare metabolic diseases. 20 February 2018
Indianapolis, USA-based Eli Lilly and South Korea’s Hanmi Pharmaceutical have shut down a Phase II trial testing the Bruton's tyrosine kinase (BTK) inhibitor HM71224 in rheumatoid arthritis (RA). 20 February 2018
In an era of consequential transformation in the healthcare delivery, compounding pharmacies market is charting a profitable growth curve. 20 February 2018
In recent years, a small non-profit research organization in Boston, Massachusetts, has quietly acquired a significant amount of influence over pricing negotiations in the gargantuan US market for prescription pharmaceuticals. 19 February 2018
Apricus Biosciences saw its market value take a nosedive on Friday following news that the company had received a complete response letter (CRL) for the New Drug Application of Vitaros (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction. 19 February 2018
In a dramatic reversal of fortunes, a US District court in Delaware has rescinded a prior decision compelling Gilead Sciences to pay $2.5 billion in damages to Merck & Co. 19 February 2018
The Turnbull government will provide two new ground-breaking flu vaccines to over three million Australians aged 65 years and over - free of charge, Prime Minister Malcolm Turnbull and Minister of Health Greg Hunt revealed in a joint statement on Sunday. 19 February 2018
The global rheumatoid arthritis drugs/therapeutics market size was valued at $20.3 billion in 2016, and is set to expand at a CAGR of 4.6%. 19 February 2018
Days after announcing it would commercialize its adrenal insufficiency (AI) therapy Alkindi (hydrocortisone) in Europe, London-based Diurnal has lined up a commercialization deal in Australia and New Zealand. 19 February 2018